Selected research
Industry Growth & Trends
Global Pulmonary Embolism Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Pulmonary Embolism Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Pulmonary Embolism Therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche, Daiichi Sankyo, Bristol-Myers Squibb and Boehringer Ingelheim International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Pulmonary Embolism Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Pulmonary Embolism Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Embolism Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Embolism Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Pulmonary Embolism Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Pulmonary Embolism Therapeutics Market by Company
Johnson & Johnson
F. Hoffmann-La Roche
Daiichi Sankyo
Bristol-Myers Squibb
Boehringer Ingelheim International
Pulmonary Embolism Therapeutics Segment by Type
Oral
Parenteral
Pulmonary Embolism Therapeutics Segment by Application
Adult
Child
Pulmonary Embolism Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Embolism Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Embolism Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Embolism Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Pulmonary Embolism Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Parenteral
Applications
- Adult
- Child
Companies covered
- Johnson & Johnson
- F. Hoffmann-La Roche
- Daiichi Sankyo
- Bristol-Myers Squibb
- Boehringer Ingelheim International
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Pulmonary Embolism Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Pulmonary Embolism Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Pulmonary Embolism Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Pulmonary Embolism Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Pulmonary Embolism Therapeutics Market Size (2021-2032)
- 1.5.1 North America Pulmonary Embolism Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Pulmonary Embolism Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Pulmonary Embolism Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Pulmonary Embolism Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Pulmonary Embolism Therapeutics Market Size Growth Rate (2021-2032)
2 Pulmonary Embolism Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Oral
- 2.1.2 Parenteral
- 2.2 Global Pulmonary Embolism Therapeutics Market Size by Type
- 2.2.1 Global Pulmonary Embolism Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Pulmonary Embolism Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Pulmonary Embolism Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Pulmonary Embolism Therapeutics Market Size by Regions
- 2.3.1 North America Pulmonary Embolism Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Pulmonary Embolism Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Pulmonary Embolism Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Pulmonary Embolism Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Pulmonary Embolism Therapeutics Market Size Breakdown by Type (2021-2026)
3 Pulmonary Embolism Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Adult
- 3.1.2 Child
- 3.2 Global Pulmonary Embolism Therapeutics Market Size by Application
- 3.2.1 Global Pulmonary Embolism Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Pulmonary Embolism Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Pulmonary Embolism Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Pulmonary Embolism Therapeutics Market Size by Regions
- 3.3.1 North America Pulmonary Embolism Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Pulmonary Embolism Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Pulmonary Embolism Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Pulmonary Embolism Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Pulmonary Embolism Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Pulmonary Embolism Therapeutics Industry Trends
- 4.2 Pulmonary Embolism Therapeutics Industry Drivers
- 4.3 Pulmonary Embolism Therapeutics Industry Opportunities and Challenges
- 4.4 Pulmonary Embolism Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Pulmonary Embolism Therapeutics Revenue (2021-2026)
- 5.2 Global Pulmonary Embolism Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Pulmonary Embolism Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Pulmonary Embolism Therapeutics Company, Product Type & Application
- 5.5 Global Pulmonary Embolism Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Pulmonary Embolism Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Pulmonary Embolism Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Pulmonary Embolism Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Pulmonary Embolism Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Johnson & Johnson Pulmonary Embolism Therapeutics Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 F. Hoffmann-La Roche
- 6.2.1 F. Hoffmann-La Roche Company Information
- 6.2.2 F. Hoffmann-La Roche Business Overview
- 6.2.3 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Product Portfolio
- 6.2.5 F. Hoffmann-La Roche Recent Developments
- 6.3 Daiichi Sankyo
- 6.3.1 Daiichi Sankyo Company Information
- 6.3.2 Daiichi Sankyo Business Overview
- 6.3.3 Daiichi Sankyo Pulmonary Embolism Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Daiichi Sankyo Pulmonary Embolism Therapeutics Product Portfolio
- 6.3.5 Daiichi Sankyo Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Boehringer Ingelheim International
- 6.5.1 Boehringer Ingelheim International Company Information
- 6.5.2 Boehringer Ingelheim International Business Overview
- 6.5.3 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Product Portfolio
- 6.5.5 Boehringer Ingelheim International Recent Developments
7 North America
- 7.1 North America Pulmonary Embolism Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Pulmonary Embolism Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Pulmonary Embolism Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Pulmonary Embolism Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Pulmonary Embolism Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Pulmonary Embolism Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Pulmonary Embolism Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Pulmonary Embolism Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Pulmonary Embolism Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Pulmonary Embolism Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Pulmonary Embolism Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst